• LAST PRICE
    2.0600
  • TODAY'S CHANGE (%)
    Trending Down-0.2200 (-9.6491%)
  • Bid / Lots
    2.0500/ 1
  • Ask / Lots
    2.1100/ 2
  • Open / Previous Close
    2.3100 / 2.2800
  • Day Range
    Low 2.0600
    High 2.3568
  • 52 Week Range
    Low 2.0600
    High 40.9800
  • Volume
    223,319
    above average

Search Criteria

Filter search criteria using below inputs

Click on magnifying glass icon to search

Search Criteria - - - Stocks (0)
CompanyCountrySymbol
Select an index
Price Comparison Graph. See accessible table below
1 Day Comparison Chart Accessibility Table. Thursday's close: 2.28
TimeVolumeGNLX
09:32 ET345542.335
09:38 ET1002.3
09:41 ET6002.3
09:48 ET1002.3
09:52 ET1002.301
09:54 ET1002.31
09:56 ET1002.3
09:57 ET3002.305
09:59 ET5002.33
10:01 ET3252.315
10:06 ET67682.32
10:12 ET23782.3026
10:17 ET1002.3
10:19 ET8632.315
10:21 ET4002.31
10:32 ET2752.3
10:33 ET4002.3306
10:35 ET5672.3354
10:39 ET1002.34
10:44 ET1002.29
10:46 ET2002.29
10:50 ET2002.29
10:51 ET1002.315
10:57 ET1002.29
11:00 ET1002.29
11:02 ET1802.29
11:06 ET3502.2908
11:11 ET2002.28
11:18 ET4532.275
11:20 ET34012.27
11:31 ET4732.28
11:36 ET1002.27
11:40 ET1002.27
11:42 ET37482.22
11:44 ET9702.21
11:47 ET1002.2
11:49 ET31612.2
11:51 ET41732.18
11:54 ET23002.19
11:56 ET1302.21
12:00 ET2002.2
12:05 ET1002.18
12:09 ET2252.1972
12:14 ET2002.18
12:16 ET5382.18
12:20 ET14952.19
12:32 ET3002.1999
12:34 ET2002.185
12:36 ET11002.2
12:41 ET1002.2
12:43 ET2002.21
12:45 ET2002.205
12:48 ET3002.205
12:50 ET1002.2
12:52 ET1002.2
12:54 ET11032.21
12:59 ET3002.215
01:01 ET3002.2199
01:06 ET1002.2105
01:08 ET2002.21
01:10 ET1002.2
01:12 ET1002.21
01:15 ET1002.21
01:19 ET1002.2
01:21 ET1862.2
01:24 ET1002.2
01:28 ET24472.19
01:30 ET1022.16
01:32 ET1002.16
01:35 ET2002.16
01:37 ET1002.16
01:39 ET1002.165
01:42 ET5002.1692
01:46 ET2002.15
01:50 ET1002.15
01:51 ET6002.15
01:55 ET1002.16
01:57 ET17852.17
02:00 ET4302.17
02:04 ET3132.18
02:08 ET2202.17
02:09 ET1002.18
02:11 ET10002.163
02:15 ET8702.16
02:20 ET1002.15
02:22 ET24282.15
02:24 ET1002.14
02:26 ET3002.14
02:27 ET6852.15
02:29 ET1712.14
02:31 ET1002.13
02:33 ET1002.14
02:40 ET1002.13
02:42 ET3002.14
02:45 ET8812.13
02:47 ET4362.1202
02:49 ET3002.12
02:51 ET7252.12
02:54 ET14172.135
02:58 ET1002.14
03:00 ET5412.14
03:03 ET1002.14
03:05 ET1002.14
03:09 ET57762.13
03:16 ET2002.11
03:18 ET6002.09
03:20 ET26532.12
03:25 ET5002.12
03:27 ET1002.11
03:30 ET8002.115
03:32 ET5002.1
03:34 ET5002.09
03:36 ET1002.09
03:38 ET17002.09
03:39 ET4002.09
03:41 ET3312.09
03:43 ET4502.07
03:45 ET7102.0808
03:48 ET1002.08
03:50 ET2002.075
03:52 ET10072.06
03:54 ET53272.065
03:56 ET15002.065
03:57 ET4002.07
03:59 ET474602.06
Data delayed at least 15 minutes.
Industry Peers Overview Table
Company sortableMarket Cap sortableP/E Ratio (TTM) sortableEPS Growth (5yr) sortable
United StatesGNLX
Genelux Corp
70.8M
-2.1x
---
United StatesSLS
Sellas Life Sciences Group Inc
70.5M
-1.1x
---
United StatesSER
Serina Therapeutics Inc
69.3M
-0.6x
---
United StatesCVM
CEL-SCI Corp
69.9M
-2.0x
---
United StatesANEB
Anebulo Pharmaceuticals Inc
69.5M
-7.4x
---
United StatesENTX
Entera Bio Ltd
72.3M
-7.1x
---
As of 2024-06-23

Company Information

Genelux Corporation is a late clinical-stage biopharmaceutical company. The Company is focused on developing a pipeline of next-generation oncolytic viral immunotherapies for patients suffering from aggressive and/or difficult-to-treat solid tumor types. Its clinical and preclinical product candidates are intended to selectively kill tumor cells and induce a robust immune response against a patient’s tumor neoantigens. Its product candidate, Olvi-Vec (olvimulogene nanivacirepvec), is a proprietary, modified strain of the vaccinia virus (VACV), a stable deoxyribonucleic acid (DNA) virus with a large engineering capacity. Olvi-Vec is developed for the treatment of multiple cancers based on the results of preclinical studies that suggest Olvi-Vec has the potential to infect and directly kill a wide range of tumor cell types in vitro and in vivo and produce an anti-tumor immune response. Its portfolio also include oncolytic vaccinia immunotherapy clinical candidates.

Contact Information

Headquarters
2625 Townsgate Road, Suite 230WESTLAKE VILLAGE, CA, United States 91361
Phone
805-267-9889
Fax
302-636-5454

Executives

Chairman of the Board, President, Chief Executive Officer
Thomas Zindrick
Chief Financial Officer
Lourie Zak
Vice President of Pharmaceutical Development, General Manager of Manufacturing
Joseph Cappello
Vice President - Clinical Trial Operations
Tony Yu
General Counsel, Corporate Secretary
Sean Ryder

Our Ratings feature offers company-specific research ratings from providers such as First Call, S&P and Argus.

Open a New Account, or Login if you're a client.

You have access to a comprehensive selection of independent research reports from providers such as TD Securities, S&P, INK, and Argus.

Open a New Account, or Login if you're a client.

Fundamentals Table
Market Cap
$70.8M
Revenue (TTM)
$8.0K
Shares Outstanding
34.4M
Dividend Yield
0.00%
Annual Dividend Rate
---
Ex-Dividend Date
01-01-01
Pay Date
01-01-01
Beta
---
EPS
$-0.98
Book Value
$0.74
P/E Ratio
-2.1x
Price/Sales (TTM)
8,845.6
Price/Cash Flow (TTM)
---
Operating Margin
-327,750.00%
*GAAP = prior to non-GAAP analyst adjusted earnings.

Our Calendar feature allows you to view a wide selection of market and company events, including earnings, dividends, splits, rating changes, guidance, and more. Access past, current and future events in WebBroker.

Open a New Account, or Login if you're a client.